A preliminary report of a phase 1b dose escalation study of OX40 agonist MOXR0916 in combination with atezolizumab in patients with advanced solid tumours showed good tolerability, and an expansion phase was conducted on selected tumour types (Table 2) [84]. Here, TNFRSF4 is linked to neoplasm.